Exelixis Inc Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Exelixis Inc payments for repurchase of common stock for the quarter ending 2026-07-03 was $322.97M, a 6.97% increase year-over-year.
- Exelixis Inc payments for repurchase of common stock for the quarter ending 2026-04-03 was $430.35M, a 51.57% increase year-over-year.
- Exelixis Inc payments for repurchase of common stock for the quarter ending 2026-01-02 was $257.62M, a 35.30% increase year-over-year.
- Exelixis Inc payments for repurchase of common stock for the quarter ending 2025-10-03 was $104.03M, a 772.26% increase year-over-year.
- Exelixis Inc payments for repurchase of common stock for fiscal 2026 was $947.51M, a 45.32% increase from fiscal 2025.
- Exelixis Inc payments for repurchase of common stock for fiscal 2025 was $652.03M, a 18.47% increase from fiscal 2023.
- Exelixis Inc payments for repurchase of common stock for fiscal 2023 was $550.38M.
- Exelixis Inc payments for repurchase of common stock for fiscal 2022 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-07-03 | $322.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.11B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-04-03 | $430.35M 10-Q · filed 2026-05-05 | $1.09B derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-01-02 | $257.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $947.51M 10-K · filed 2026-02-10 |
| 2025-10-03 | $104.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $880.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-07-04 | $301.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $788.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-04-04 | $283.93M 10-Q · filed 2026-05-05 | $750.59M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-01-03 | $190.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $652.03M 10-K · filed 2026-02-10 |
| 2024-09-27 | $11.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $670.92M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-28 | $264.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-28 | $875.83M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-29 | $185.38M 10-Q · filed 2025-05-13 | $735.75M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-29 | $209.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $550.38M 10-K · filed 2026-02-10 |
| 2023-09-29 | $216.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $341.08M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $124.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $124.24M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $0.00 10-Q · filed 2024-04-30 | |
| 2022-12-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $0.00 10-K · filed 2025-02-11 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | |
| 2021-12-31 | $0.00 10-K · filed 2024-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |